nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

28.08.2020 | Review – Clinical Oncology

Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature

verfasst von: Laiyan Zhou, Mai Zhang, Rui Li, Jianxin Xue, You Lu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Immune checkpoint inhibitors are associated with clinical benefit in lung cancer. However, response patterns to immunotherapy, including pseudoprogression and hyperprogression, are difficult to diagnose, and their mechanisms remain unclear. This review aimed to describe two response patterns observed in lung cancer, namely pseudoprogression and hyperprogression, including their epidemiology, diagnostic characteristics, and plausible mechanisms.

Methods

We performed a comprehensive literature search in the PubMed database, using keywords “pseudoprogression”, “hyperprogression”, and “lung cancer”, among others. The literature was examined for pseudoprogression and hyperprogression characteristics and plausible mechanisms.

Results

Pseudoprogression manifests in multiple forms; however, the immune system-related response criteria and biopsy data are helpful to make accurate diagnosis. Serological biomarkers, such as neutrophil-to-lymphocyte ratio (NLR) and circulating tumor DNA (ctDNA), might help distinguish pseudoprogression from true progression. The incidence of hyperprogression ranges within 5–19.2%, depending on definition. The unique response pattern of rapid progression is observed not only with immunotherapy, but also with other treatment regimens. Molecular mutations and amplifications may result in hyperprogression; however, the exact mechanism remains unclear.

Conclusion

Atypical response patterns, such as pseudoprogression and hyperprogression, are increasingly common in clinical practice. Immune-related response criteria can help diagnose pseudoprogression. Molecular mechanisms of hyperprogression remain unclear. Biomarkers for pseudoprogression and hyperprogression are required.

Albert NL, Weller M, Suchorska B et al (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 18(9):1199–1208. https://doi.org/10.1093/neuonc/now058CrossRefPubMedPubMedCentral

Alexander JL, Gillespie PJ, Edelstyn GA (1976) Serial bone scanning using technetium 99m diphosphonate in patients undergoing cyclical combination chemotherapy for advanced breast cancer. Clin Nucl Med 1:13–17. https://doi.org/10.1097/00003072-197606000-00004CrossRef

Bagley SJ, Kothari S, Aggarwal C et al (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1–7. https://doi.org/10.1016/j.lungcan.2017.01.013CrossRefPubMed

Barrón F, Cardona AF, Corrales L et al (2018) Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation. J Thorac Dis 10:2166–2178. https://doi.org/10.21037/jtd.2018.03.106CrossRefPubMedPubMedCentral

Beer L, Hochmair M, Prosch H (2018) Pitfalls in the radiological response assessment of immunotherapy. Memo 11(2):138–143. https://doi.org/10.1007/s12254-018-0389-xCrossRefPubMedPubMedCentral

Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026. https://doi.org/10.1056/nejmoa1613683CrossRefPubMedPubMedCentral

Bensch F, van der Veen EL, Lub-de Hooge MN et al (2018) Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 24(12):1852–1858. https://doi.org/10.1038/s41591-018-0255-8CrossRefPubMed

Berghoff AS, Preusser M (2018) New developments in brain metastases. Ther Adv Neurol Disord 11:1756286418785502. https://doi.org/10.1177/1756286418785502CrossRefPubMedPubMedCentral

Bohnsack O, Hoos A, Ludajic K (1070P) 1070P Adaptation of the immune-related response criteria: irRECIST. Ann Oncol 25(Supplement 4):iv361–iv372. https://doi.org/10.1093/annonc/mdu342.23CrossRef

Borcoman E, Kanjanapan Y, Champiat S et al (2019) Novel patterns of response under immunotherapy. Ann Oncol 30(3):385–396. https://doi.org/10.1093/annonc/mdz003CrossRefPubMed

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643CrossRefPubMedPubMedCentral

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135. https://doi.org/10.1056/NEJMoa1504627CrossRefPubMedPubMedCentral

Champiat S, Dercle L, Ammari S et al (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 23(8):1920–1928. https://doi.org/10.1158/1078-0432.ccr-16-1741CrossRefPubMed

Champiat S, Ferrar R, Massard C et al (2018) Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 15(12):748–762. https://doi.org/10.1038/s41571-018-0111-2CrossRefPubMed

Chao HS, Chang CP, Chiu CH et al (2009) Bone scan flare phenomenon in nonsmall-cell lung cancer patients treated with gefitinib. Clin Nucl Med 34:346–349. https://doi.org/10.1097/rlu.0b013e3181a344dfCrossRefPubMed

Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541–3543. https://doi.org/10.1200/JCO.2015.61.6870CrossRefPubMedPubMedCentral

Curioni-Fontecedro A, Ickenberg C, Franzen D et al (2018) Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab. Ann Oncol 28:2040–2041. https://doi.org/10.1093/annonc/mdx233CrossRef

De Cecco CN, Darnell A, Rengo M et al (2012) Dual-energy CT: oncologic applications. AJR Am J Roentgenol 199:S98–S105. https://doi.org/10.2214/AJR.12.9207CrossRefPubMed

Desar IM, Mulder SF, Stillebroer AB et al (2009) The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol 48:927–931. https://doi.org/10.1080/02841860902974167CrossRefPubMed

Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297–1306. https://doi.org/10.1007/s00262-008-0642-yCrossRefPubMed

Doherty MK, Jao K, Shepherd FA et al (2015) Central nervous system pseudoprogression in a patient treated with PD-1 checkpoint inhibitor. J Thorac Oncol 10:e100–101. https://doi.org/10.1097/JTO.0000000000000587CrossRefPubMed

Dulos J, Carven GJ, van Boxtel SJ et al (2012) PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35:169–178. https://doi.org/10.1097/CJI.0b013e318247a4e7CrossRefPubMed

Ellestad KK, Thangavelu G, Ewen CL et al (2014) PD-1 is not required for natural or peripherally induced regulatory T cells: severe autoimmunity despite normal production of regulatory T cells. Eur J Immunol 44:3560–3572. https://doi.org/10.1002/eji.201444688CrossRefPubMed

Erasmus JJ, Gladish GW, Broemeling L et al (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21(13):2574–2582. https://doi.org/10.1200/jco.2003.01.144CrossRefPubMed

Ferrara R, Mezquita L, Texier M et al (2018) Hyperprogressive Disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 4(11):1543–1552. https://doi.org/10.1001/jamaoncol.2018.3676CrossRefPubMedPubMedCentral

Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1038/sj.bdj.2016.860CrossRefPubMedPubMedCentral

Galldiks N, Kocher M, Ceccon G et al (2020) Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. Neuro-oncology 22(1):17–30. https://doi.org/10.1093/neuonc/noz147CrossRefPubMed

Gandara DR, von Pawel J, Mazieres J et al (2018) Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study. J Thorac Oncol 13:1906–1918. https://doi.org/10.1016/j.jtho.2018.08.2027CrossRefPubMed

Garassino M, Cho BC, Kim JH et al (2018) Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol 19(4):521–536. https://doi.org/10.1016/s1470-2045(18)30144-xCrossRefPubMedPubMedCentral

Guibert N, Mazieres J, Delaunay M et al (2017) Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. Oncotarget 8(23):38056–38060. https://doi.org/10.18632/oncotarget.16935CrossRefPubMedPubMedCentral

Guthrie GJ, Charles KA, Roxburgh CS et al (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Re Oncol Hematol 88:218–230. https://doi.org/10.1016/j.critrevonc.2013.03.010CrossRef

Hammer M, Bagley S, Aggarwal C et al (2019) Thoracic imaging of non-small cell lung cancer treated with anti-programmed death receptor-1 therapy. Curr Probl Diagn Radiol 48(2):142–147. https://doi.org/10.1067/j.cpradiol.2018.01.005CrossRefPubMed

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRefPubMed

Hendriks LEL, Henon C, Auclin E et al (2019) Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol 14(7):1244–1254. https://doi.org/10.1016/j.jtho.2019.02.009CrossRefPubMed

Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer: a randomised controlled trial. Lancet 387:1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7CrossRefPubMed

Hodi FS, Oble DA, Drappatz J et al (2008) CTLA-4 blockade with ipilimumab induces signifificant clinical benefifit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5(9):557–561. https://doi.org/10.1038/ncponc1183CrossRefPubMed

Hodi FS, Hwu WJ, Kefford R et al (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab. J Clin Oncol 34:1510–1517. https://doi.org/10.1200/JCO.2015.64.0391CrossRefPubMedPubMedCentral

Huang B, Pan PY, Li Q et al (2006) Gr-1+CD115+immature myeloid suppressor cells mediate the development of tumorinduced T regulatory cells and T cell anergy in tumor-bearing host. Cancer Res 66:1123–1131. https://doi.org/10.1158/0008-5472.can-05-1299CrossRefPubMed

Huang RY, Francois A, McGray AR et al (2017) Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology 6:e1249561. https://doi.org/10.1080/2162402x.2016.1249561CrossRefPubMed

Iacovelli R, Massari F, Albiges L et al (2015) Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma. Eur Urol 68:154–160. https://doi.org/10.1016/j.eururo.2014.10.034CrossRefPubMed

Jensen TJ, Goodman AM, Kato S et al (2019) Genome-wide sequencing of cell-free DNA identifies copy-number alterations that can be used for monitoring response to immunotherapy in cancer patients. Mol Cancer Ther 18(2):448–458. https://doi.org/10.1158/1535-7163.mct-18-0535CrossRefPubMed

Kang MH, Go SI, Song HN et al (2014) The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer 111:452–460. https://doi.org/10.1038/bjc.2014.317CrossRefPubMedPubMedCentral

Kas B, Talbot H, Ferrara R et al (2020) Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer. JAMA Oncol 6(7):1039–1046. https://doi.org/10.1001/jamaoncol.2020.1634CrossRefPubMedPubMedCentral

Kato R, Hayashi H, Tanizaki J et al (2017a) Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab. ESMO Open 2:e000145. https://doi.org/10.1136/esmoopen-2016-000145CrossRefPubMedPubMedCentral

Kato S, Goodman A, Walavalkar V et al (2017b) Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 23:4242–4250. https://doi.org/10.1158/1078-0432.ccr-16-3133CrossRefPubMedPubMedCentral

Kazandjian D, Keegan P, Suzman DL et al (2017) Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version1.1-defined disease progression in clinical trials. Semin Oncol 44:3–7. https://doi.org/10.1053/j.seminoncol.2017.01.001CrossRefPubMed

Kim HK, Heo MH, Lee HS et al (2017) Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemother Pharmacol 80(3):591–598. https://doi.org/10.1007/s00280-017-3396-4CrossRefPubMed

Kim EY, Park I, Kim YS (2019a) Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer. Thorac Cancer 10(4):1016–1018. https://doi.org/10.1111/1759-7714.12994CrossRefPubMedPubMedCentral

Kim HK, Baek SW, Jeong Y et al (2019b) Pseudoprogression presenting as intestinal perforation in non-small cell lung cancer treated with anti-PD-1: a case report. Mol Clin Oncol 11(2):132–134. https://doi.org/10.3892/mco.2019.1871CrossRefPubMedPubMedCentral

Kim CG, Kim KH, Pyo K-H et al (2019c) Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol 30(7):1104–1113. https://doi.org/10.1093/annonc/mdz123CrossRefPubMed

Kim SH, Choi CM, Lee DH et al (2020) Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-020-03293-9CrossRefPubMedPubMedCentral

Krupitskaya Y, Eslamy HK, Nguyen DD et al (2009) Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. J Thorac Oncol 4(3):429–431. https://doi.org/10.1097/jto.0b013e3181989e12CrossRefPubMed

Kuriyama Y, Kim YH, Nagai H et al (2013) Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer. Case Rep Oncol 6:430–433. https://doi.org/10.1159/000354756CrossRefPubMedPubMedCentral

Kurra V, Sullivan RJ, Gainor JF et al (2016) Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes. J Clin Oncol 34(15_suppl):6580–6580. https://doi.org/10.1200/JCO.2016.34.15_suppl.6580CrossRef

Lamichhane P, Karyampudi L, Shreeder B et al (2017) IL-10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res 77:6667–6678. https://doi.org/10.1158/0008-5472.CAN-17-0740CrossRefPubMedPubMedCentral

Langen KJ, Galldiks N, Hattingen E et al (2017) Advances in neuro-oncology imaging. Nat Rev Neurol 13(5):279–289. https://doi.org/10.1038/nrneurol.2017.44CrossRefPubMed

Lau SCM, Leighl NB (2019) Hyperprogressive disease with immunotherapy: new directions. J Thorac Dis 11:S1877–S1880. https://doi.org/10.21037/jtd.2019.08.88CrossRefPubMedPubMedCentral

Lee JH, Long GV, Menzies AM et al (2018) Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol 4(5):717–721. https://doi.org/10.1001/jamaoncol.2017.5332CrossRefPubMedPubMedCentral

Lemieux J, Guimond J, Laberge F et al (2002) The bone scan flare phenomenon in nonsmall-cell lung cancer. Clin Nucl Med 27:486–489. https://doi.org/10.1097/00003072-200207000-00004CrossRefPubMed

Lin X, Lu T, Xie Z et al (2019) Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: a case report and literature review. Thorac Cancer 10(5):1272–1275. https://doi.org/10.1111/1759-7714.13048CrossRefPubMedPubMedCentral

Liu G, Chen T, Li R et al (2018) Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: a case report. Thorac Cancer 9(9):1190–1193. https://doi.org/10.1111/1759-7714.12799CrossRefPubMedPubMedCentral

Lo Russo G, Moro M, Sommariva M et al (2019) AntibodyFc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade. Clin Cancer Res 25:989–999. https://doi.org/10.1158/1078-0432.CCR-18-1390CrossRefPubMed

Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22:231–237. https://doi.org/10.1016/j.coi.2010.01.009CrossRefPubMed

Masaki K, Ryuya E, Hiroyuki K et al (2018) Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: a case series. Thorac Cancer 9:1782–1787. https://doi.org/10.1111/1759-7714.12894CrossRef

Matos I, Martin-Liberal J, Hierro C et al (2018) Incidence and clinical implications of a new definition of hyperprogression(HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1)trials. J Clin Oncol 36(15 suppl):3032–3032. https://doi.org/10.1200/jco.2018.36.15_suppl.3032CrossRef

Matsuo N, Azuma K, Hattori S et al (2019) Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor. Int J Cancer 144(5):1170–1179. https://doi.org/10.1002/ijc.31923CrossRefPubMed

Melian M, Lorente D, Aparici F et al (2018) Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment. Thorac Cancer 9(12):1770–1773. https://doi.org/10.1111/1759-7714.12873CrossRefPubMedPubMedCentral

Mellema WW, Burgers SA, Smit EF (2015) Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report. Lung Cancer 87:201–203. https://doi.org/10.1016/j.lungcan.2014.11.014CrossRefPubMed

Mezquita L, Auclin E, Ferrara R et al (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4:351–357. https://doi.org/10.1001/jamaoncol.2017.4771CrossRefPubMedPubMedCentral

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594. https://doi.org/10.4065/83.5.584CrossRefPubMed

Nishino M, Guo M, Jackman DM et al (2011) CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad radiol 18(1):54–62. https://doi.org/10.1016/j.acra.2010.08.021CrossRefPubMed

Nishino M, Giobbie-Hurder A, Gargano M et al (2013) Developing a common language for tumor response to immunotherapy: immune related response criteria using unidimensional measurements. Clin Cancer Res 19(14):3936–3943. https://doi.org/10.1158/1078-0432.ccr-13-0895CrossRefPubMedPubMedCentral

Nishino M, Ramaiya NH, Chambers ES et al (2016) Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer 4:84–93. https://doi.org/10.1186/s40425-016-0193-2CrossRefPubMedPubMedCentral

Pop O, Pirvu A, Toffart AC et al (2012) Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. J Thorac Oncol 7:e1–e2. https://doi.org/10.1097/jto.0b013e318257fc1dCrossRefPubMed

Popat V, Gerber DE (2019) Hyperprogressive disease: a distinct effect of immunotherapy? J Thorac Dis 11:S262–S265. https://doi.org/10.21037/jtd.2019.01.97CrossRefPubMedPubMedCentral

Powles T, Kayani I, Sharpe K et al (2013) A prospective evaluation of VEGF targeted treatment cessation in metastatic clear cell renal cancer. Ann Oncol 24:2098–2103. https://doi.org/10.1093/annonc/mdt130CrossRefPubMed

Powles T, Duran I, van der Heijden MS et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391(10122):748–757. https://doi.org/10.1016/s0140-6736(17)33297-xCrossRefPubMed

Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER (2004) Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 22(14):2800–2807. https://doi.org/10.1200/JCO.2004.10.197CrossRefPubMed

Ricciuti B, Genova C, Bassanelli M et al (2019) Safety and efficacy of nivolumab in patients with advanced non-small-cell lung cancer treated beyond progression. Clin Lung Cancer 20:178.e2–185.e2. https://doi.org/10.1016/j.cllc.2019.02.001CrossRef

Riely GJ, Kris MG, Zhao B et al (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150–5155. https://doi.org/10.1158/1078-0432.ccr-07-0560CrossRefPubMed

Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated nonsmall cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265. https://doi.org/10.1016/s0140-6736(16)32517-xCrossRefPubMed

Saada-Bouzid E, Defaucheux C, Karabajakian A et al (2017) Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 28(7):1605–1611. https://doi.org/10.1093/annonc/mdx178CrossRefPubMed

Saenger YM, Wolchok JD (2008) The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 8:1PubMedPubMedCentral

Sage PT, Francisco LM, Carman CV et al (2013) The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol 14:152–161. https://doi.org/10.1038/ni.2496CrossRefPubMed

Sanmamed MF, Perez-Gracia JL, Schalper KA et al (2017) Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients. Ann Oncol 28(8):1988–1995. https://doi.org/10.1093/annonc/mdx190CrossRefPubMedPubMedCentral

Sarfaty M, Moore A, Dudnik E et al (2017) Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: a case report. Medicine (Baltimore) 96:e5951. https://doi.org/10.1097/MD.0000000000005951CrossRef

Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143–e152. https://doi.org/10.1016/s1470-2045(17)30074-8CrossRefPubMedPubMedCentral

Shepherd FA, Papadimitrakopoulou V, Mok T et al (2018) Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial. J Clin Oncol 36:abstr 9027. https://doi.org/10.1200/jco.2018.36.15_suppl.9027CrossRef

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590CrossRefPubMed

Singavi AK, Menon S, Kilari D et al (1140PD) Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI)—analysis of somatic alterations (SAs). Ann Oncol 28:1140PD. https://doi.org/10.1093/annonc/mdx376.006CrossRef

Skoulidis F, Goldberg ME, Greenawalt DM et al (2018) STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 8:822–835. https://doi.org/10.1158/2159-8290.CD-18-0099CrossRefPubMedPubMedCentral

Skoulidis F, Arbour KC, Hellmann MD et al (2019) Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. J Clin Oncol 37:abstr 102. https://doi.org/10.1200/jco.2019.37.15_suppl.102CrossRef

Solinas C, Porcu M, Hlavata Z et al (2017) Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Crit Rev Oncol Hematol 120:13–21. https://doi.org/10.1016/j.critrevonc.2017.09.017CrossRefPubMed

Song P, Zhang J, Shang C et al (2019) Curative effect assessment of immunotherapy for non-small cell lung cancer: the “blind area” of immune response evaluation criteria in solid tumors (iRECIST). Thoracic Cancer 10(4):587–592. https://doi.org/10.1111/1759-7714.13010CrossRefPubMedPubMedCentral

Taniguchi Y, Tamiya A, Isa S et al (2017) Predictive factors for poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. Anticancer Res 37(10):5857–5862. https://doi.org/10.21873/anticanres.12030CrossRefPubMed

Tanizaki J, Hayashi H, Kimura M et al (2016) Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Lung Cancer 102:44–48. https://doi.org/10.1016/j.lungcan.2016.10.014CrossRefPubMed

Tazdait M, Mezquita L, Lahmar J et al (2018) Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 88:38–47. https://doi.org/10.1016/j.ejca.2017.10.017CrossRefPubMed

Templeton AJ, McNamara MG, Šeruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124. https://doi.org/10.1093/jnci/dju124CrossRefPubMed

Vrankar M, Unk M (2018) Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. Radiol Oncol 52(4):365–369. https://doi.org/10.2478/raon-2018-0037CrossRefPubMedPubMedCentral

Wang Q, Gao J, Wu X et al (2018) Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol 58:125–135. https://doi.org/10.1016/j.intimp.2018.03.018CrossRefPubMed

Weiss GJ, Beck J, Braun DP et al (2017) Tumor cell-free DNA copy number instability predicts therapeutic response to immunotherapy. Clin Cancer Res 23(17):5074–5081. https://doi.org/10.1158/1078-0432.ccr-17-0231CrossRefPubMed

Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria. Clin Cancer Res 15:7412–7420. https://doi.org/10.1158/1078-0432.CCR-09-1624CrossRefPubMed

Wolter P, Beuselinck B, Pans S et al (2009) Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 48:621–624. https://doi.org/10.1080/02841860802609574CrossRefPubMed

Xiong D, Wang Y, Singavi AK et al (2018) Immunogenomic landscape contributes to hyperprogressive disease after Anti-PD-1 immunotherapy for cancer. iScience 9:258–277. https://doi.org/10.1016/j.isci.2018.10.021CrossRefPubMedPubMedCentral

Yang JJ, Chen HJ, Yan HH et al (2013) Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 79:33–39. https://doi.org/10.1016/s0923-7534(20)33797-2CrossRefPubMed

Yang K, Blanco DB, Neale G et al (2017) Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling. Nature 548:602–606. https://doi.org/10.1038/nature23665CrossRefPubMedPubMedCentral

Zer A, Sung MR, Walia P et al (2018) Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 19(5):426–434.e1. https://doi.org/10.1016/j.cllc.2018.04.008CrossRefPubMed

Zhao B, James LP, Moskowitz CS et al (2009) Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology 252(1):263–272. https://doi.org/10.1148/radiol.2522081593CrossRefPubMedPubMedCentral

Zhou C, Imamura F, Cheng Y et al (2019) Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. J Clin Oncol 37:abstr 9020. https://doi.org/10.1200/jco.2019.37.15_suppl.9020CrossRef

Titel: Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature
verfasst von: Laiyan Zhou
Mai Zhang
Rui Li
Jianxin Xue
You Lu
Publikationsdatum: 28.08.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03360-1

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy

Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma

UV-type specific alteration of miRNA expression and its association with tumor progression and metastasis in SCC cell lines

Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation

Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18–12

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie